We Innovate Diagnostic Efficiency
Gentian develops and manufactures high quality, in vitro diagnostic (IVD) reagents for a wide range of clinical chemistry analysers. Our product lines of laboratory tests, for diverse diagnostic targets, provide high accuracy and fast results for both human and veterinary healthcare.
We believe that our innovative and accurate diagnostic products lead to improved laboratory efficiency, better decision making in the clinical setting and therefore can improve patients’ outcomes.
Innovative Products – Global Reach
Gentian performs production, R&D, marketing and distribution from our headquarters in Moss, Norway and our representative offices. We serve the global market for human and veterinary medical diagnostic tests via our OEM partners and key distributors as well as directly through Gentian Diagnostics AB, our Swedish based distribution subsidiary. Our approach is collaborative and adaptable, without compromising quality, in order to meet our customers needs.
Our reagents are developed using avian antibodies and our proprietary Nanosense technology. Importantly, they can be adapted for use on all major clinical chemistry analysers. The current portfolio and pipeline of efficient and accurate reagents span areas of inflammations, severe infections, kidney failures and congestive heart failures and veterinary healthcare.
Gentian at a Glance
Quality & Accuracy
Get in touch
Want to know more about Gentian as a company or our products. Fill out the form below or send an email to email@example.com
Quality is at the core of our everyday work and is a driving factor in achieving diagnostic efficiency.
All companies in the Gentian Diagnostics group continuously evaluate and improve their operations to increase the satisfaction of our customers, employees, owners and the markets we operate in. We make sure that every new product meets the highest performance standards.
Quality Management System
Gentian integrates its Quality Management System and Design Control Standards within all areas of the company, including Research, Development and Production.
Gentian Diagnostics ASA is listed on the Oslo Stock Exchange and consists of the subsidiary; Gentian AS. Gentian AS is headquartered in Moss, Norway with a representative office in China and with distribution subsidiaries; Gentian USA, Inc. and Gentian Diagnostics AB (Sweden).
The Gentian Diagnostics companies have interdisciplinary and international teams working on global solutions to innovate diagnostic efficiency.
Our people convert knowledge and research into products that improve diagnostic efficiency.
At Gentian we combine interdisciplinarity and experience with scientific knowledge. The Gentian team is highly international and has experience from global in vitro diagnostic companies. As a result, we offer improved solutions, improved clinical accuracy and diagnostic efficiencies.
Gentian was started by brothers Erling and Bård Sundrehagen in 2001. Having originally worked together during the founding of Axis (later Axis-Shield ltd, Alere inc. and now Abbott), they were eager to start a new, innovative venture together in the diagnostics field. From a small office in central Moss, 50 km south of Oslo, Norway, speaking to laboratory doctors across Scandinavia, they quickly identified a gap in the IVD market for a high quality, sensitive, turbidimetric cystatin C immunoassay.
The Gentian Cystatin C Immunoassay was launched in 2006 and after fast uptake in Sweden, an FDA 510k clearance was achieved in 2008. The Beijing representative office was opened in 2010 and Gentian USA Inc. established 2012 to expand the global reach of Gentian. Gentian’s multi-platform assay was adapted for use on instruments in centralised laboratories worldwide and OEM partners were established.
The company soon outgrew the their original facilities and opened up a dedicated laboratory and office space in 2011 in Moss, which was further expanded in 2016. The team expanded and development began on multiple new products.
On 14th December, 2016, Gentian Diagnostics AS was admitted to the Oslo Stock Exchange list ‘Merkur Market’. In May 2021 Gentian Diagnostics ASA applied for admission to trading on Oslo Børs by transfer of its current admission to trading on Euronext Growth operated by Oslo Børs. Subject to Oslo Børs' approval of the Gentian's admission application and satisfaction of any conditions for admission to trading set by Oslo Børs, Gentian expects that the first day of trading of its shares on Oslo Børs will be in the end for June 2021